Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 11, 2004. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific equity transactions and does not contain financial statements.
Material Changes
The primary material change reported is a transaction involving the GlaxoSmithKline Employee Trust ("GSK Trust"). On February 10, 2004, Abacus (GSK) Trustees Limited transferred 5,058 Ordinary shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Management Commentary and Risks
The filing notes that the GSK Trust is a discretionary trust where all current and former employees are potential beneficiaries. Consequently, three directors—Dr. J-P Garnier, Dr. T Yamada, and Mr. J D Coombe—are interested in the shares held in the trust in the same manner as other employees. No specific risks, contingencies, or unusual items regarding operations were disclosed in this text.
Investor Verification Points
- Verify the total number of shares held by the GSK Trust following the transfer of 5,058 shares.
- Confirm the specific shareholding changes for directors Dr. J-P Garnier, Dr. T Yamada, and Mr. J D Coombe resulting from the trust transaction.
- Review the terms of the SmithKline Beecham Employee Share Option Plan 1991 to understand the vesting or exercise conditions for the transferred shares.